Niagen Bioscience, Inc Financials
This page shows Niagen Bioscience, Inc (NAGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin expansion and a cash-heavy balance sheet show growth is dropping through to profit faster than operating needs rise.
From FY2023 to FY2025, revenue growth added nearly$46M while inventory stayed near$10M , a sign growth has not required much more stock on hand. That lighter working-capital intensity helps explain why the business reached$17.4M of net income in FY2025 with no long-term debt, even though operating cash flow of$13.5M still lagged accounting profit.
Profitability improved through scale, not just expense restraint: SG&A climbed to
The balance sheet now looks self-funded: cash reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Niagen Bioscience, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Niagen Bioscience, Inc scores 5.59, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($257.3M) relative to total liabilities ($29.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Niagen Bioscience, Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Niagen Bioscience, Inc generates $0.78 in operating cash flow ($13.5M OCF vs $17.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Niagen Bioscience, Inc generated $129.4M in revenue in fiscal year 2025. This represents an increase of 29.9% from the prior year.
Niagen Bioscience, Inc's EBITDA was $17.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 99.8% from the prior year.
Niagen Bioscience, Inc reported $17.4M in net income in fiscal year 2025. This represents an increase of 103.3% from the prior year.
Niagen Bioscience, Inc earned $0.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 81.8% from the prior year.
Cash & Balance Sheet
Niagen Bioscience, Inc held $64.8M in cash against $0 in long-term debt as of fiscal year 2025.
Niagen Bioscience, Inc had 80M shares outstanding in fiscal year 2025. This represents an increase of 3.1% from the prior year.
Margins & Returns
Niagen Bioscience, Inc's gross margin was 64.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the prior year.
Niagen Bioscience, Inc's operating margin was 12.6% in fiscal year 2025, reflecting core business profitability. This is up 4.8 percentage points from the prior year.
Niagen Bioscience, Inc's net profit margin was 13.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.9 percentage points from the prior year.
Niagen Bioscience, Inc's ROE was 22.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.2 percentage points from the prior year.
Capital Allocation
Niagen Bioscience, Inc invested $6.3M in research and development in fiscal year 2025. This represents an increase of 5.2% from the prior year.
Niagen Bioscience, Inc spent $251K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
NAGE Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.5M-7.0% | $33.8M-0.4% | $34.0M+9.2% | $31.1M+2.1% | $30.5M+4.7% | $29.1M+13.9% | $25.6M+12.5% | $22.7M |
| Cost of Revenue | $11.5M-5.2% | $12.1M+0.6% | $12.1M+10.7% | $10.9M-2.3% | $11.2M+2.0% | $10.9M+17.0% | $9.3M+3.3% | $9.0M |
| Gross Profit | $20.0M-8.0% | $21.7M-1.0% | $21.9M+8.4% | $20.2M+4.6% | $19.3M+6.2% | $18.2M+12.1% | $16.2M+18.6% | $13.7M |
| R&D Expenses | $1.5M-13.4% | $1.7M-4.7% | $1.8M+14.6% | $1.6M+24.6% | $1.3M-4.3% | $1.3M+1.9% | $1.3M-2.0% | $1.3M |
| SG&A Expenses | $7.2M-3.1% | $7.5M+4.9% | $7.1M-1.9% | $7.3M+40.2% | $5.2M+391.4% | $1.1M-83.3% | $6.3M+11.3% | $5.7M |
| Operating Income | $1.6M-61.4% | $4.1M-3.5% | $4.2M+33.0% | $3.2M-33.3% | $4.8M-32.9% | $7.1M+343.9% | $1.6M+725.8% | -$256K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $417K+42.8% | $292K+31.5% | $222K+73.4% | $128K-23.8% | $168K-44.9% | $305K | $0 | $0 |
| Net Income | $6.3M+52.9% | $4.1M-9.7% | $4.6M+26.8% | $3.6M-28.7% | $5.1M-29.5% | $7.2M+282.3% | $1.9M+12620.0% | -$15K |
| EPS (Diluted) | $0.07 | N/A | $0.05+25.0% | $0.04-33.3% | $0.06 | N/A | $0.02 | $0.00 |
NAGE Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $114.3M+7.4% | $106.4M+8.4% | $98.1M+7.2% | $91.5M+12.5% | $81.3M+19.1% | $68.3M+20.8% | $56.5M+4.6% | $54.0M |
| Current Assets | $105.1M+8.6% | $96.8M+3.4% | $93.6M+8.0% | $86.7M+13.7% | $76.2M+18.9% | $64.1M+23.0% | $52.1M+5.7% | $49.3M |
| Cash & Equivalents | $66.5M+2.7% | $64.8M+1.1% | $64.1M+6.3% | $60.3M+8.6% | $55.5M+24.7% | $44.5M+38.2% | $32.2M+16.2% | $27.7M |
| Inventory | $24.0M+17.6% | $20.4M+8.7% | $18.8M+30.4% | $14.4M+28.8% | $11.2M+21.7% | $9.2M-12.8% | $10.5M-8.4% | $11.5M |
| Accounts Receivable | $13.1M+34.2% | $9.7M+14.5% | $8.5M-11.9% | $9.7M+36.9% | $7.1M-9.2% | $7.8M+9.5% | $7.1M-9.2% | $7.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $32.0M+7.1% | $29.9M+8.8% | $27.5M+0.5% | $27.3M+5.1% | $26.0M+17.2% | $22.2M+0.1% | $22.2M-5.0% | $23.3M |
| Current Liabilities | $22.8M+14.6% | $19.9M-12.3% | $22.7M+1.7% | $22.3M+7.2% | $20.8M+16.1% | $17.9M+1.4% | $17.7M-0.9% | $17.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $82.3M+7.6% | $76.5M+8.3% | $70.7M+10.1% | $64.2M+16.0% | $55.3M+20.1% | $46.1M+34.1% | $34.4M+11.9% | $30.7M |
| Retained Earnings | -$158.2M+3.8% | -$164.5M+2.4% | -$168.7M+2.6% | -$173.2M+2.0% | -$176.8M+2.8% | -$181.9M+3.8% | -$189.1M+1.0% | -$191.0M |
NAGE Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M-275.8% | $679K-81.6% | $3.7M+195.4% | $1.3M-84.1% | $7.9M-8.2% | $8.6M+145.6% | $3.5M+1423.9% | -$264K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $5.2M+5293.1% | -$101K-320.8% | -$24K+82.2% | -$135K-321.9% | -$32K+53.6% | -$69K-228.6% | -$21K-75.0% | -$12K |
| Financing Cash Flow | -$2.3M-2762.5% | -$80K-154.1% | $148K-96.0% | $3.7M+20.5% | $3.1M-17.2% | $3.7M+260.7% | $1.0M+74.3% | $596K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $2.4M | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
NAGE Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.5%-0.7pp | 64.1%-0.4pp | 64.5%-0.5pp | 65.0%+1.6pp | 63.4%+0.9pp | 62.5%-1.0pp | 63.5%+3.3pp | 60.2% |
| Operating Margin | 5.0%-7.1pp | 12.1%-0.4pp | 12.5%+2.2pp | 10.2%-5.4pp | 15.7%-8.8pp | 24.4%+18.2pp | 6.3%+7.4pp | -1.1% |
| Net Margin | 20.1%+7.9pp | 12.2%-1.3pp | 13.5%+1.9pp | 11.6%-5.0pp | 16.6%-8.0pp | 24.6%+17.3pp | 7.3%+7.4pp | -0.1% |
| Return on Equity | 7.7%+2.3pp | 5.4%-1.1pp | 6.5%+0.9pp | 5.6%-3.5pp | 9.2%-6.4pp | 15.6%+10.1pp | 5.5%+5.5pp | -0.1% |
| Return on Assets | 5.5%+1.7pp | 3.9%-0.8pp | 4.7%+0.7pp | 3.9%-2.3pp | 6.2%-4.3pp | 10.5%+7.2pp | 3.3%+3.4pp | -0.0% |
| Current Ratio | 4.61-0.3 | 4.86+0.7 | 4.12+0.2 | 3.88+0.2 | 3.66+0.1 | 3.57+0.6 | 2.95+0.2 | 2.76 |
| Debt-to-Equity | 0.390.0 | 0.390.0 | 0.39-0.0 | 0.43-0.0 | 0.47-0.0 | 0.48-0.2 | 0.64-0.1 | 0.76 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Niagen Bioscience, Inc's annual revenue?
Niagen Bioscience, Inc (NAGE) reported $129.4M in total revenue for fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Niagen Bioscience, Inc's revenue growing?
Niagen Bioscience, Inc (NAGE) revenue grew by 29.9% year-over-year, from $99.6M to $129.4M in fiscal year 2025.
Is Niagen Bioscience, Inc profitable?
Yes, Niagen Bioscience, Inc (NAGE) reported a net income of $17.4M in fiscal year 2025, with a net profit margin of 13.4%.
What is Niagen Bioscience, Inc's EBITDA?
Niagen Bioscience, Inc (NAGE) had EBITDA of $17.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Niagen Bioscience, Inc's gross margin?
Niagen Bioscience, Inc (NAGE) had a gross margin of 64.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Niagen Bioscience, Inc's operating margin?
Niagen Bioscience, Inc (NAGE) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Niagen Bioscience, Inc's net profit margin?
Niagen Bioscience, Inc (NAGE) had a net profit margin of 13.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Niagen Bioscience, Inc's return on equity (ROE)?
Niagen Bioscience, Inc (NAGE) has a return on equity of 22.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Niagen Bioscience, Inc's operating cash flow?
Niagen Bioscience, Inc (NAGE) generated $13.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Niagen Bioscience, Inc's total assets?
Niagen Bioscience, Inc (NAGE) had $106.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Niagen Bioscience, Inc spend on research and development?
Niagen Bioscience, Inc (NAGE) invested $6.3M in research and development during fiscal year 2025.
What is Niagen Bioscience, Inc's current ratio?
Niagen Bioscience, Inc (NAGE) had a current ratio of 4.86 as of fiscal year 2025, which is generally considered healthy.
What is Niagen Bioscience, Inc's debt-to-equity ratio?
Niagen Bioscience, Inc (NAGE) had a debt-to-equity ratio of 0.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Niagen Bioscience, Inc's return on assets (ROA)?
Niagen Bioscience, Inc (NAGE) had a return on assets of 16.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Niagen Bioscience, Inc's Altman Z-Score?
Niagen Bioscience, Inc (NAGE) has an Altman Z-Score of 5.59, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Niagen Bioscience, Inc's Piotroski F-Score?
Niagen Bioscience, Inc (NAGE) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Niagen Bioscience, Inc's earnings high quality?
Niagen Bioscience, Inc (NAGE) has an earnings quality ratio of 0.78x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Niagen Bioscience, Inc?
Niagen Bioscience, Inc (NAGE) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.